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Introduction
Breast cancer is the most common cancer in women.1 About 
40% of women diagnosed will be postmenopausal and have 
tumors that are sensitive to estrogen or progesterone.2 For 
these women, aromatase inhibitors are standard pharmaco-
logical treatment, which has been shown to improve dis-
ease-free survival.3,4 However, aromatase inhibitors act 
by blocking the production of estrogen, profoundly deplet-
ing oestrogen levels within days of administration. 
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Abstract
Introduction: Women with breast cancer are often prescribed aromatase inhibitors, which can cause rapid loss of 
bone mass leading to significant potential for morbidity. Vibration training has been shown to be helpful in reducing bone 
turnover in postmenopausal women without cancer. Aim: To examine the effect of vibration stimulus on markers of 
bone turnover in breast cancer patients receiving aromatase inhibitors. Methods: Thirty-one breast cancer survivors 
undergoing treatment with aromatase inhibitors were randomized to vibration stimulus (n = 14) or usual care control (n = 
17). Low-frequency and low-magnitude vibration stimulus (27-32 Hz, 0.3g) was delivered in supervised sessions via standing 
on a vibration platform for 20 minutes, 3 times per week for 12 weeks. The primary outcome was blood markers of bone 
resorption (serum N-telopeptide X/creatine) and formation (serum type 1 procollagen N-terminal propeptide; P1NP). 
Other study outcomes body composition as well as measures of physical functioning. Outcomes were compared between 
groups using analysis of covariance adjusted for baseline values as well as time on aromatase inhibitors. Outcomes: On 
average, participants were 61.5 years old and overweight (ie, body mass index = 28.5 kg/m2). Following vibration training, 
there was no significant difference between groups for bone resorption (adjusted group difference 0.5, P = .929) or 
formation (adjusted group difference 5.3, P = .286). There were also no changes in any measure of physical functioning 
body composition. Conclusions: Short-term low-magnitude vibration stimulus does not appear to be useful for reducing 
markers of bone turnover secondary to aromatase inhibitors in breast cancer patients; nor is it useful in improving physical 
function or symptoms. However, further investigations with larger samples and higher doses of vibration are warranted. 
Trial Registration: Australian and New Zealand Clinical Trials Registry (ACTRN12611001094965).
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Consequently, this results in a severe loss of bone mass 
where the inhibition of estrogen causes a marked increase in 
bone resorption (ie, breakdown),4 resulting in net bone loss 
at twice the rate of normal physiological postmenopausal 
bone loss.5,6 Low bone mineral density is a significant 
health problem as it increases the risk of fracture; the most 
serious complication of osteoporosis, which is associated 
with significantly increased morbidity, mortality, and health 
care expenditure.7 The loss of bone density and increased 
incidence of fragility fractures associated with aromatase 
inhibitor use is higher when compared to other treatments 
such as tamoxifen.8
The current treatment to reverse increased bone resorp-
tion is administration of oral bisphosphonates. However, 
these are costly pharmaceutical interventions with little 
benefit observed in bisphosphonate use beyond the first 5 to 
10 years.9 While generally well tolerated, they have low 
compliance levels (20%-57% over 1 year) due to the rigid 
dosing requirements5 and are associated with negative side 
effects, including suppression of bone formation, gastroin-
testinal irritations, and its long term use is associated with 
secondary cancers.10 Exercise interventions that involve an 
increased loading on the bone such as resistance training, 
jumping activity, and other weightbearing activities, have 
also been shown to improve bone density in pre- and post-
menopausal women when performed regularly.11 However, 
research to date regarding the role of exercise for bone 
health in breast cancer survivors reports poor intervention 
adherence,12-15 as well as a lack of evidence for improve-
ments in bone mineral density.12-17 Investigation of other 
supportive care interventions aimed at decreasing bone 
resorption in breast cancer patients on aromatase inhibitors 
is required.
Whole-body vibration training (WBV) is a relatively 
new form of therapy that has been shown in certain popula-
tions to increase bone density, develop muscle function, and 
improve balance.18,19 This time efficient form of treatment 
involves having the patient stand on a platform that pro-
duces vertical accelerations at a specific frequency and 
amplitude in order to stimulate physiological responses in 
the bone and muscle tissue. Low-magnitude vibration train-
ing has previously been shown to reduce the rate of bone 
resorption in postmenopausal women.20 Vibration exposure 
3 times per week reduced a marker of bone resorption in 
postmenopausal women without cancer by 34.6% over 8 
weeks.20 By comparison, reductions of 25% in markers of 
bone resorption have been reported in postmenopausal 
women with osteoporosis/osteopenia following walking 
programs of 12 months duration.21 Vibration may be more 
accessible to those with greater symptoms and lower mobil-
ity when compared with exercise training, given the low 
physical demand of standing.
In this study, we examined the effect of vibration stimu-
lus on markers of bone turnover in postmenopausal breast 
cancer patients receiving aromatase inhibitor therapy. We 
hypothesized that the application of low-magnitude vibra-
tion stimulus for 12 weeks would decrease the bone resorp-
tion marker, N-telopeptide X/creatinine (Ntx/Cr), compared 
with no vibration exposure. In addition, we explored the 
effects of vibration stimulus on body composition and phys-
ical functioning.
Patients and Methods
Participants
Women undergoing aromatase inhibitor (AI) therapy were 
recruited between August 2012 and November 2014 from 
Perth, Australia through referral from oncologists. 
Participants were eligible if they were willing to continue 
taking any bone altering medications or supplements they 
were previously taking for the duration of the study, includ-
ing calcium, vitamin D, or hormone replacement therapy 
(HRT); able to stand unassisted for sustained periods of 
time (ie, 20 minutes); received medical clearance from their 
general practitioner to participate. Exclusion criteria 
included taking bisphosphonates, cognitive impairment; 
contraindications to vibration platform training (including 
pacemaker and fracture within the past six months); diagno-
sis of bone metastases, and the diagnosis of diseases other 
than osteoporosis affecting bone. The study protocol was 
approved by the Edith Cowan University Human Research 
Committee and was registered with the Australian and New 
Zealand Clinical Trials Registry (ACTRN12611001094965). 
All participants gave informed written consent prior to 
enrolment.
Design
The study was a single blinded randomized controlled trial, 
with an intention-to-treat analytic strategy. The intervention 
consisted of a 12-week whole body vibration exposure pro-
gram. Serum and urine markers of bone turnover, body 
composition and physical function, muscular strength, bone 
density, quality of life, and pain/stiffness of joints were 
measured at baseline and postintervention. All testing was 
conducted at the Edith Cowan University, Exercise 
Medicine Research Institute, and training was conducted 
either there or at Sir Charles Gairdner Hospital Department 
of Physiotherapy, Perth, Australia.
Randomization
Participants were randomized into a vibration-training 
group, or a control group following completion of baseline 
assessments. Randomization was performed using com-
puter-generated, randomly permuted blocks by a researcher 
who was not involved in testing and training of participants. 
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Participants were stratified by bone mineral density T-score 
obtained via DXA (dual-energy X-ray absorptiometry) scan 
(ie, ≤1 vs >1), and current physical activity participation 
obtained via self-report from Godin Leisure Time Exercise 
Questionnaire,22 (ie, moderate and vigorous physical activ-
ity <150 vs ≥150). Participants were informed of their 
group allocation by means of sealed opaque envelopes 
given to them after completion of all baseline testing.
Vibration Exposure
Low-frequency, low-magnitude vibration was applied 
(30 Hz, 0.1 mm, 0.3g) using a vibration platform (Juvent 
Medical, Somerset, NJ, USA). This is consistent with cur-
rent research that suggests that low magnitude is anabolic to 
bone23 as it does not cause damage to physiology possibly 
associated with high-magnitude vibration.24 Past literature 
has reported that low frequency vibration has greatest trans-
mission up the axial skeleton, with this transmissibility 
decreasing as higher vibration frequencies are used.25 
Recently, a meta-analysis exploring the effect of whole-
body vibration on bone loss in postmenopausal women 
showed that low-magnitude vibration (defined as <1g) was 
effective in reducing bone loss, whereas high-magnitude 
was not.26 All participants were instructed to stand on the 
vibration platform with their feet shoulder width apart, knees 
locked, and hands by their side to receive maximum vibra-
tion exposure. The protocol was performed with partici-
pants’ shoes removed to prevent any attenuation of vibration 
that may result from footwear. Sessions included 20 minutes 
of vibration exposure 3 times a week for 12 weeks.
Control
The control group received usual care from their physician 
throughout the 12-week period. Those assigned to the con-
trol group were given no additional treatment or intervention 
but were placed on a waiting list giving them access to the 
vibration training facilities at the completion of the study.
Outcomes
Outcome measures were conducted at baseline (prior to 
randomization) and postintervention.
Primary Outcomes
Markers of bone formation (serum type 1 procollagen 
N-terminal propeptide [P1NP]) and resorption 
(N-telopeptide X/creatinine [NTx/Cr]) were assessed via 
blood and urine tests performed without batching by an 
independent NATA-accredited laboratory blinded to group 
allocation. Blood samples were collected between 72 and 
120 hours following the last vibration exposure session to 
standardize previously reported acute bout effects on mark-
ers of bone metabolism.27
Secondary Outcomes
Demographic and health history information was collected 
via questionnaire at baseline assessment. Baseline 25-OH 
vitamin D status was assessed by blood test, and analysis 
performed without batching by an independent NATA 
(National Association of Testing Authorities, Australia)–
accredited laboratory blinded to group allocation.
Anthropometric Measures, Body Composition, and Bone Mineral 
Density. Height and weight were assessed by stadiometer 
(Seca GmbH & Co KG, Hamburg, Germany). Waist and hip 
circumference were assessed as a horizontal measure taken 
at the narrowest part of the torso or between the iliac crest 
and 12th rib, and the maximal circumference of the hip.28 
Whole body dual-energy X-ray absorptiometry scan (DXA; 
Hologic Discovery A, Waltham, MA, USA) was used to 
assess whole body and regional lean and fat mass.29 Addi-
tionally, to characterize the study population, DXA scans 
were used to assess bone mineral density (BMD, g/cm2) of 
total hip (ie, femoral neck), spine (ie, lumbar spine L2-L4), 
and whole body.
Physical Functioning. Physical functioning was assessed by a 
series of tests. Cardiovascular fitness was assessed by the 
400-m walk test.30 Functional ability was assessed via 
repeated chair rise and stair climb.31 To assess ambulatory 
ability, electronic timing gates were used to assess usual, 
fast-paced and backward 6-m walk.32 Functional tests were 
performed in triplicate with standardized rest-times given 
between trials.31 Static balance was assessed in six different 
positions (feet apart in parallel stance, feet together in paral-
lel stance, half tandem stance, tandem stance, one-legged 
stance, one-legged stance eyes closed), without the use of 
assistive device for a maximum of 15 seconds in each posi-
tion. Total static balance is calculated by summing the time 
recorded for each of the six stances.33 Maximal strength was 
by a 1-repetition maximum test for lower body (leg press) 
and upper body (chest press).34
Patient-Reported Outcomes. Patient-rated outcomes were 
assessed using well-validated self-report questionnaire. The 
Western Ontario and McMaster Universities Arthritis Index 
(WOMAC) was applied to assess joint pain and stiffness 
and difficulty with daily activities.35 Fatigue was assessed 
by the Functional Assessment of Cancer Therapy–Fatigue 
subscale.36 Exercise behavior was assessed by a validated 
modified version of the Godin Leisure Time Exercise 
Questionnaire.22,37
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Sample Size Calculations
Sample size estimates were driven by hypothesized differ-
ences between the vibration and control subjects in NTx 
over the study. Changes were derived from a previous study 
using vibration training in postmenopausal women.20 A pri-
ori, 2-tailed power calculations at an alpha of .05 and beta of 
.20 gave an actual power of 0.82 for a total sample size of 40 
using G-Power software (University of Trier, Germany).
Statistical Analysis
Data were analyzed using the SPSS statistical software 
package (version 22.0, IBM Corp, Armonk, NY, USA). Data 
distributions were inspected for normality. Normally distrib-
uted data were described using mean ± SD and non-normally 
distributed data using median and interquartile range (IQR). 
Non-normally distributed continuous variables were log-
transformed prior to use with parametric statistics if possi-
ble, otherwise nonparametric statistics were used. Analyses 
included standard descriptive statistics, unpaired t tests, chi-
square, and Mann-Whitney U tests. Analysis of covariance 
(ANCOVA) models were constructed to compare groups, 
using the change scores as the dependent variable, with 
adjustment for baseline score and time on aromatase inhibi-
tors. Although this difference between groups for time on AI 
therapy at baseline was not statistically significant (P = .06), 
we felt the difference between groups was clinically mean-
ingful and therefore included it as a covariate in the analysis. 
Association between variables was determined by Pearson 
correlation. An intention-to-treat analysis was performed 
with missing outcome scores imputed from participants’ 
baseline scores (last observation carried forward). An alpha 
level of .05 was set as the criterion for statistical signifi-
cance. Clinical relevance was assessed relative to the mean-
ingfulness of bone and musculoskeletal outcomes compared 
with existing literature.
Results
Thirty-one participants were enrolled into the study. 
Recruitment ended at the completion of the funding period. 
Participant flow is presented in Figure 1. On average, par-
ticipants attended 91.5% (range 78%-100%) of WBV train-
ing sessions.
Figure 1. Flow of subject progress through each stage of the trial.
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Participant Characteristics
Baseline participant characteristics are presented in Table 1. 
The cohort had a mean age of 61.6 ± 8.3 years. The partici-
pants were on average overweight (body mass index = 28.8 
± 4.7 kg/m2), and the majority were nonsmokers. Baseline 
characteristics of the participants did not differ between 
groups, except for duration of AI therapy with participants 
in the vibration group having been on treatment for longer 
than the control (median 19 months, IQR 26.5 vs median 3 
months IQR 13.5; P = .06). Approximately half (53.3%) of 
the participants were taking anastrozole, with the remainder 
taking letrozole. Osteoporosis was present in only 4 partici-
pants, with no group differences (P = .35). Baseline levels 
of 25-OH vitamin D, P1NP, and NTx/Cr were not different 
between groups (P > .53).
Markers of Bone Resorption and Formation
Results are presented in Table 2. Following 12 weeks of 
vibration training, NTx/Cr levels did not change differen-
tially between groups (adjusted group difference −0.5, P = 
.929). Change in NTx/Cr was significantly negatively asso-
ciated with duration of aromatase inhibitors (r = −0.46, P = 
.009), as well as baseline vitamin D (r = −0.41, P = .026). 
The change in NTx/Cr was not associated with changes in 
body composition (Ps > .657) or changes in physical func-
tion (Ps > .147), with the exception of chair rise, which was 
significantly negatively correlated (r = −0.38, P = .039).
P1NP levels did not change differentially between 
groups over the 12-week intervention (adjusted group dif-
ference +5.3, P = .286). Changes in P1NP were not associ-
ated with aromatase inhibitor duration (r = 0.80, P = .670), 
Table 1. Demographics and Health Status.a
Variable Whole Cohort (n = 31) Vibration (n = 14) Control (n = 17) P
Age, years 61.6 ± 8.3 61.6 ± 9.2 61.6 ± 7.8 .98
Vitamin D, nmol/L 86.8 ± 25.9 85.6 ± 25.8 87.8 ± 26.8 .83
Body mass index,b kg/m2 28.8 ± 4.7 28.4 ± 3.9 29.1 ± 5.3 .72
Education, % .06
 High school 83.8 85.7 81.2  
 Undergraduate 9.7 0.0 18.8  
 Postgraduate 6.5 14.3 0.0  
Smoking status, % .15
 Past smoker 35.5 35.7 35.2  
 Current smoker 9.7 0.0 5.7  
Alcohol drinks per week 3.8 ± 4.8 3.3 ± 2.8 4.3 ± 6.1 .59
Caffeine drinks per week 20.3 ± 10.1 21.4 ± 7.3 19.3 ± 12.3 .59
Months of AI therapy at baseline, median (IQR) 10 (20) 3 (13.5) 19 (26.5) .06c
Bone mineral density, g/cm3  
 Hip 0.874 ± 0.105 0.871 ± 0.093 0.877 ± 0.116 .88
 Spine 1.011 ± 0.177 0.987 ± 0.159 1.032 ± 0.193 .49
 Whole body 1.053 ± 0.106 1.03 ± 0.061 1.073 ± 0.131 .24
Abbreviations: AI, aromatase inhibitor; IQR, interquartile range.
aAll data presented as mean ± SD unless otherwise specified.
bBody mass index: an indicator of body fat calculated by weight (kg)/height2 (m). Normal values range from 18.5 to 24.9kg/m2. Values >25 kg/m2 are 
considered overweight, and >30 kg/m2 are considered obese.
cMann-Whitney test.
Table 2. Changes in Markers of Bone Resorption and Formation Following the Intervention.
Vibration Group (Mean ± SD) Control Group (Mean ± SD)
Adjusted Group Difference in Mean 
Changea
 Pre Post Pre Post Mean Change (95% CI) P
NTx/Cr (BCE/mmol Cr) 43.3 ± 20.0 45.9 ± 25.6 39.0 ± 16.4 38.7 ± 12.9 0.5 (–10.6 to 11.5) .929
P1NP (µg/L) 62.3 ± 27.0 64.0 ± 25.6 62.2 ± 25.3 59.5 ± 26.2 5.3 (–4.7 to 15.2) .286
Abbreviations: BCE, bone collagen equivalent; Cr, creatinine; NTx, N-telopeptide X; P1NP, type 1 procollagen N-terminal propeptide.
a Adjusted for baseline value and time on aromatase inhibitors at baseline.
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or baseline vitamin D levels (r = 0.089, P = .645). Changes 
in P1NP were not associated with changes in body compo-
sition (Ps > .135) or physical function (Ps > .089), with the 
exception of chair rise, which was significantly negatively 
correlated (r = −0.36, P = .049).
Secondary Outcomes
All results of secondary outcomes are reported in Tables 3 
and 4. No measures of physical functioning changed dif-
ferentially between groups (Ps > .140). Changes in maxi-
mal strength and functional ability are illustrated in Figures 
2 and 3. Body composition measures of lean and fat mass 
remained unchanged after 12 weeks (Ps > .548). There was 
no difference between groups for changes in joint pain, 
stiffness and difficulty with daily activities as measured by 
the WOMAC scale (P > 0.051). The intervention had no 
significant effect on fatigue (P = .079).
Adverse Events
Three adverse events occurred during the trial. One partici-
pant reported syncope during a training session. Another 
experienced increased swelling in her arm after exercise 
testing. A third experienced extreme distress on being allo-
cated to the control group. All participants were able to con-
tinue with the intervention and the intervention was 
otherwise well tolerated.
Discussion
Aromatase inhibitor use secondary to breast cancer results in 
significant bone loss that puts women at risk for morbidity. 
This study examined the effect of short-term, low amplitude 
and low g-force vibration stimulus on markers of bone turn-
over in postmenopausal breast cancer patients receiving aro-
matase inhibitor therapy. Following 12 weeks of vibration 
training, there were no differences between intervention and 
control groups for markers of bone turnover, physical func-
tioning, body composition, arthralgia symptoms, or fatigue.
Vibration training was well-tolerated by participants. 
Twenty minutes of vibration exposure 3 times a week for 12 
weeks was not effective in changing markers of bone resorp-
tion or bone formation in the current study. Previous studies 
have shown beneficial effects on bone metabolism after 
vibration training in postmenopausal women,20 and after 
combined aerobic and resistance training in female cancer 
survivors.38 However changes observed in bone metabolism 
Table 3. Changes in Physical Functioning and Patient-Rated Outcomes Following the Intervention.
Vibration Group (Mean ± SD) Control Group (Mean ± SD)
Adjusted Group Difference 
in Mean Changea
 Pre Post Pre Post Mean (95% CI) P
Physical function
 Leg press 1RM, kg, median (IQR) 65.0 (48.8) 71.3 (46.2) 63.0 (50.0) 65.2 (47.9) 3.5 (0.0, 10.0) .140b
 Chest press 1RM, kg,c median (IQR) 22.5 (12.5) 23.8 (11.3) 17.5 (12.5) 25.0 (11.9) 0.0 (0.0, 2.5) .402b
 Seated row press 1RM, kg,c median  
  (IQR)
45.0 (7.9) 46.2 (5.0) 42.8 (11.2) 45.0 (15.7) 0.0 (0.0, 2.9) .347b
 400-m walk, s 264.1 ± 31.0 256.3 ± 33.8 273.5 ± 41.2 269.0 ± 36.3 –5.0 (–20.5, 10.5) .514
 Chair rise, reps 11.2 ± 2.3 11.0 ± 1.6 11.4 ± 2.6 10.5 ± 2.5 0.65 (–0.59, 1.88) .292
 Stair climb, s 5.2 ± 1.46 5.30 ± 1.70 5.88 ± 2.20 5.09 ± 1.69 1.04 (–0.42, 2.49) .154
 6-m walk usual pace, s 4.60 ± 0.49 4.39 ±0.0.41 4.56 ± 0.71 4.47 ± 0.54 0.65 (–0.59, 1.88) .292
 6-m walk fast pace, s 3.35 ± 0.32 3.36 ± 0.36 3.33 ± 0.58 3.44 ± 0.46 –1.46 (–0.35, 0.60) .158
 6-m backward walk, s 18.56 ±4.69 16.9 ± 4.34 17.3 ± 6.55 16.1 ± 6.2 –0.94 (–3.80, 1.91) .503
 Balance 80.0 ± 6.9 77.8 ± 6.7 75.8 ± 6.8 77.3 ± 6.9 3.04 (–7.56, 1.53) .185
Patient-rated outcomes
 WOMAC Pain, median (IQR) 0.0 (1.0) 0.0 (3.3) 1.0 (6.8) 2.0 (6.8) 0.0 (0.0, 1.0) .334b
 WOMAC Stiffness, median (IQR) 0.0 (1.3) 1.0 (2.0) 2.0 (3.0) 2.5 (3.8) 0.0 (0.0, 1.0) .224b
 WOMAC Difficulty, median (IQR) 0.5 (5.5) 2.5 (8.5) 7.0 (20.0) 6.0 (19.8) 0.0 (0.0, 3.0) .063b
 WOMAC Total, median (IQR) 1.0 (7.3) 4.5 (13.8) 9.0 (27.0) 9.5 (30.0) 0.0 (–1.0, 4.3) .051b
 Fatigued 13.1 ± 6.4 11.6 ± 4.4 13.4 ± 8.8 14.2 ± 7.9 –2.9 (–6.2, 0.4) .079
Abbreviations: 1RM, one repetition maximum; IQR, interquartile range; WOMAC, Western Ontario and McMaster Universities Arthritis Index (higher 
scores indicate worse symptoms).
aAdjusted for baseline value and time on aromatase inhibitor at baseline.
bMann-Whitney test.
cn = 28 due to inability to complete upper body strength measures.
dFatigue was assessed by the Functional Assessment of Cancer Therapy–Fatigue subscale (higher scores indicate greater fatigue).
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may not consistently translate into clinically or statistically 
significant improvements in bone density or strength. A 
recent meta-analysis suggests that vibration training in post-
menopausal women has little effect on bone outcomes, as 
measured by DXA, at 6-month follow-up.39 Comparison 
with other studies, however, is problematic because of large 
variations in study durations and dose of vibration.40
A range of pharmaceutical interventions are available to 
improve bone mass. Bisphosphonates such as alendronate 
increase bone mineral density by approximately 5% to 
15%, with better results observed in the lumbar spine and 
more modest results at the femoral neck.41,42 Different 
forms of exercise have been shown to be effective in 
improving bone density. Combined impact protocols, 
impact exercise training combined with resistance training, 
is the most effective option for maintaining or preserving 
bone mineral density in postmenopausal women.43 A meta-
analysis of the effect of exercise on bone mineral density on 
postmenopausal women showed a small effect at both the 
lumbar spine and femoral neck of a magnitude that is simi-
lar to vitamin D and calcium supplementation, but smaller 
than observed with bisphosphonates.42,44 Recent research 
suggests that 12 months of aerobic and resistance training 
does not improve bone mineral density in postmenopausal 
breast cancer patients taking aromatase inhibitors16 or in 
those who have completed treatment.13 The authors suggest 
that the amount of exercise required to sufficiently provide 
osteogenic stimulus for healthy postmenopausal women 
could be inadequate for those on aromatase inhibitor ther-
apy.16 The same could be true for the level of WBV stimulus 
tested in this study.
The mechanism by which vibration stimulus affects 
bone is not fully understood. It has been hypothesized that 
the anabolic effect of vibration on bone may be a result of 
stress exerted on bone through repeated loading and unload-
ing, resulting in increased fluid flow.45 Greater activation of 
muscle through enhanced sensitivity of mechanoreceptors, 
and increased osteogenesis in osteoblasts have also been 
observed, suggesting that vibration is anabolic at a cellular 
level.46,47 Human studies have reported potential benefits in 
bone,23,24,48-55 muscle function,52,54,56,57 balance and preven-
tion of falls,58 reduction of muscle spasticity in those with 
cerebral palsy,59 and postural control in those with 
Table 4. Changes in Body Composition and Bone Mineral Density Outcomes Following the Intervention.
Vibration Group (Mean ± SD) Control Group (Mean ± SD)
Adjusted Group Difference in 
Mean Changea
Body Composition Pre Post Pre Post Mean (95% CI) P
Waist to hip ratio 0.83 ± 0.07 0.82 ± 0.06 0.83 ± 0.67 0.83 ± 0.70 0.012 (–0.30, 0.55) .548
Whole body mass, kg 75.1 ± 13.3 74.4 ± 12.3 75.6 ± 14.3 75.6 ± 14.2 –0.1 (–2.7, 2.4) .912
Whole body lean mass, kg 41.4 ± 5.3 41.3 ± 5.4 43.3 ± 5.7 43.0 ± 5.7 0.3 (–0.9, 1.6) .573
Appendicular lean mass, kg 16.5 ± 2.4 16.2 ± 2.4 17.4 ± 2.5 17.2 ± 2.4 0.1 (–0.9, 1.1) .820
Whole body fat mass, kg 30.7 ± 8.3 31.0 ± 7.5 30.9 ± 9.6 31.1 ± 9.3 0.1 (–1.0, 1.2) .803
Whole body fat percentage, % 40.9 ± 4.6 41.3 ± 4.1 40.2 ± 5.7 40.6 ± 5.3 0.1 (–1.2, 1.4) .890
Trunk fat mass, kg 14.6 ± 4.6 14.9 ± 4.1 14.6 ± 5.4 14.7 ± 5.3 –0.2 (–1.1, 0.7) .607
aAdjusted for baseline value and time on aromatase inhibitor at baseline.
Figure 2. Median change in lower body strength (leg press) at 
12 weeks.
Figure 3. Mean change in stair climb time at 12 weeks.
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Parkinson’s disease.60 However, the optimal time course, 
dose, and frequency of vibration to elicit optimal changes in 
bone are currently not established, with a wide variety of 
vibration exposure protocols leading to variation in changes 
in bone outcomes. Inconsistency in study nomenclature, 
design, and measurement of bone outcomes, reporting of 
adverse effects and noncompliance, highlight the lack of 
uniformity and small pool of information available on the 
effects of vibration on bone.61 While improvements in BMD 
have been demonstrated in postmenopausal women follow-
ing 6 months of WBV training,54 the lack of effect observed 
in the current study may be partially explained by the short 
study duration, the dose of exposure, or the lack of intermit-
tent vibration exposure.62 However, the challenge of over-
coming bone loss during AI therapy is great. While treatment 
with bisphosphonates has shown to be effective in improv-
ing BMD, in the adjuvant setting among women undergo-
ing AI therapy such treatment does not prevent fractures.63
No improvements in physical function or body composition 
were observed in the current study. Previous research indicates 
that WBV can improve muscular strength as well as physical 
functioning in older women,64 as well as those with fibromyal-
gia.65 Even low doses of vibration have previously improved 
physical function, with increases in lower limb muscle strength 
in older adults of 14% observed after 13 weeks.66
Given the lack of change in physical function or muscle 
strength, the lack of change in body composition is unsur-
prising. Whole body vibration has previously been shown 
to improve body composition in other clinical populations, 
such as people with rheumatoid arthritis67 and obese 
women.68 However these interventions used a much higher 
dose of vibration of approximately 5g to 6g compared to 
our 0.3g—a dose chosen for its osteogenic effects.23 It has 
been suggested that for muscular adaptation, higher fre-
quencies and amplitudes are optimal.69
Arthralgia is a commonly reported side effect of AI therapy 
with the incidence reported in clinical trials from 16.8% to 
35.9%.70 While aerobic and resistance exercise have been 
shown to improve symptoms of AI-induced arthralgia,71 we 
did not observe such an effect with WBV. Similarly, while 
numerous studies have demonstrated an improvement in can-
cer–related fatigue with exercise,72 no such effect was 
observed with WBV. As WBV has only a modest effect on 
energy expenditure and heart rate,73,74 the muscle contractions 
and perturbation of the cardiovascular system in short 20-min-
ute bouts may not be sufficient to elicit such adaptations.
This study has limitations that should be considered in 
interpreting the results. We did not reach our target sample 
size, as such we were underpowered to detect a significant 
difference between groups, although this was unlikely to have 
affected the primary outcomes given no trend was observed. 
Further research is required in order to determine if higher 
doses of vibration, intermittent vibration combined with exer-
cise on the platform, or longer duration of training (eg, 24 
weeks) can elicit beneficial effects on bone during AI therapy. 
Recent evidence from meta-analyses suggest that side-alter-
nating vibration platforms produce superior outcomes in post-
menopausal women39,75—future research should focus on this 
mode of vibration delivery. Further research into the potential 
benefits of other forms of prescribed exercise on bone health 
during AI therapy should be considered.
To our knowledge this is the first application of WBV 
therapy in breast cancer patients undergoing AI therapy. 
Well-validated outcomes measured assessed markers of 
bone turnover, body composition, as well as a comprehen-
sive assessment of physical functioning. We also report an 
excellent adherence rate to WBV training.
Conclusion
Short-term, low-amplitude and low g-force vibration stimu-
lus does not appear to be effective for altering markers of 
bone turnover secondary to aromatase inhibitors in breast 
cancer patients. There also appears to be no benefit in phys-
ical functioning, body composition, arthralgia symptoms, 
or fatigue.
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